A relationship between alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-β autoantibodies

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1371-1376

  Kim, Insub ^a   Lee, Junhee ^a   Hong, Hyun Joo ^a   Jung, Eun Sun ^a   Ku, Yun Hyi ^b   Jeong, In Kyong ^b   Cho, Young Min ^b   So, Insuk ^a   Park, Kyong Soo ^a,b   Mook Jung, Inhee ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Department of Internal Medicine ^*  (South Korea)

Author keywords

Alzheimer's disease; A autoantibody; Biomarker; Cholesterol; Type 2 diabetes mellitus

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALZHEIMER DISEASE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SERUM;

EID: 77950356619     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1332     Document Type: Article

References (26)

1. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of WHO consultation. Diabet Med 15, 539-553.
2. Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A (1999) Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
4. Pelia R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
5. Li L, Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56, 384-402.
6. Clark A,Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Copper GJ, Holman RR, TurnerRC(1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9, 151-159.
7. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci U S A 84, 8628-8632.
8. Gotz J, Ittner LM, Lim YA (2009) Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 66, 1321-1325.
9. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
10. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely, TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
11. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 10, 89-109.
12. Sohn JH, So JO., Kim H,NamEJ, Ha HJ, Kim YH, Mook-Jung I (2007) Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. Biochem Biophys Res Commun 361, 800-804.
13. Sohn JH, So JO, Hong HJ, Kim JW, Na DR, Kim M, Nam E, Ha HJ, Kim YH, Mook-Jung I (2009) Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front Biosci 14, 3879-3883.
14. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37, 943-948.
15. Moir RD, Tesitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280, 17458-17463.
16. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919.
17. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
18. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, JefferiesWA (2006) Abeta peptide immunization restores bloodbrain barrier integrity in Alzheimer disease. FASEB J 20, 426-433.
19. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
20. PanW, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to beta-amyloid decrease the blood-to-brain transfer of betaamyloid peptide. Exp Biol Med (Maywood) 227, 609-615.
21. Krentz AJ (2003) Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 5 (Suppl 1), S19-27.
22. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, PappollaMA(2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
23. Silvius JR (2003) Role of cholesterol in lipid raft formation: lessons from lipid model system. Biochim Biophys Acta 1610, 174-183.
24. Rubinstein R, Genaro AM, Motta A, Cremaschi G, Wald MR (2008) Impaired immune response in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clin Exp Immunol 154, 235-246.
25. Sakowicz M, Szutowicz A, Pawelczyk T (2005) Differential effect of insulin and elevated glucose level on adenosine transport in rat B lymphocytes. Int Immunol 17, 145-154.
26. Alexiewicz JM, Kumar D, Smogorzewski M, Massry SG (1997) Elevated cytosolic calcium and impaired proliferation of B lymphocytes in type II diabetes mellitus. Am J Kidney Dis 30, 98-104.